{"title":"建立5年总生存期作为晚期HCC临床试验的新标准","authors":"Pierre Nahon","doi":"10.1016/j.jhep.2025.05.001","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Disclosures</h2>Pr Nahon has received honoraria from and/or consults for AstraZeneca, Bristol-Myers Squibb, Eisai, and Roche. He received research grants from AstraZeneca, Bristol-Myers Squibb and Eisai.</section></section><section><section><h2>Grant Support</h2>Pierre Nahon’s research is funded in part by the European Union (GENIAL, Grant agreement ID: 101096312), French Agence Nationale de la Recherche (France 2030 DELIVER ANR-21-RHUS-0001) and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014).</section></section><section><section><h2>Declaration of Competing Interest</h2>none to declare</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"55 29 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Establishing five-year overall survival as a new standard for trials in advanced HCC\",\"authors\":\"Pierre Nahon\",\"doi\":\"10.1016/j.jhep.2025.05.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Disclosures</h2>Pr Nahon has received honoraria from and/or consults for AstraZeneca, Bristol-Myers Squibb, Eisai, and Roche. He received research grants from AstraZeneca, Bristol-Myers Squibb and Eisai.</section></section><section><section><h2>Grant Support</h2>Pierre Nahon’s research is funded in part by the European Union (GENIAL, Grant agreement ID: 101096312), French Agence Nationale de la Recherche (France 2030 DELIVER ANR-21-RHUS-0001) and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014).</section></section><section><section><h2>Declaration of Competing Interest</h2>none to declare</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"55 29 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2025.05.001\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.05.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Establishing five-year overall survival as a new standard for trials in advanced HCC
Section snippets
Disclosures
Pr Nahon has received honoraria from and/or consults for AstraZeneca, Bristol-Myers Squibb, Eisai, and Roche. He received research grants from AstraZeneca, Bristol-Myers Squibb and Eisai.
Grant Support
Pierre Nahon’s research is funded in part by the European Union (GENIAL, Grant agreement ID: 101096312), French Agence Nationale de la Recherche (France 2030 DELIVER ANR-21-RHUS-0001) and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014).
期刊介绍:
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.